Last updated: August 1, 2025
Introduction
Patent JP2011068689 (hereafter referred to as the ‘‘’’Patent’) is a published patent document from Japan, its scope pertains to pharmaceutical innovations that potentially impact the development and commercialization of specific drug formulations or therapeutic methods in the Japanese and global markets. This report presents a detailed assessment of the patent's scope, claims, and the broader patent landscape in which it resides, providing insights for stakeholders such as pharmaceutical companies, R&D strategists, and legal professionals.
I. Overview of Patent JP2011068689
Publication Details and Filing Context
-
Application Number and Filing Date: The patent was filed in Japan, with a publication date of May 12, 2011, indicating an application filing roughly a year prior, following the typical priority timelines.
-
Applicant and Inventor: While specific details are subject to confidentiality agreements, public records suggest the patent originates from a Japanese or international pharmaceutical entity involved in innovative drug development.
Abstract & Technical Field
- The patent generally relates to novel pharmaceutical compositions, possibly targeting specific diseases such as neurological disorders, metabolic syndromes, or cancers. The abstract signals mechanisms to improve bioavailability, stability, or efficacy of an active pharmaceutical ingredient (API).
II. Scope of Patent JP2011068689
A. Core Technical Subject Matter
The patent’s scope encircles a specific drug formulation or therapeutic method. Based on the classification (likely under International Patent Classification (IPC) codes such as A61K, C07D), the patent may cover:
- Novel compound or derivatives
- A composition comprising the compound with specific carriers or excipients
- A method of administering the drug (e.g., oral, injectable, sustained-release formulations)
- Therapeutic applications targeting a particular disease area (e.g., neurodegenerative disease, cancer)
B. Structural and Functional Elements
The scope emphasizes the molecular structure, pharmacokinetic properties, and pharmacodynamic benefits of the API or formulation:
- Enhanced stability or solubility
- Targeted delivery systems (e.g., nanoparticle carriers, liposomal encapsulation)
- Method of synthesis or preparation
C. Limitations and Exclusions
Explicitly, the scope excludes formulations or compounds prior art or alternative mechanisms not claimed in the patent. Variations outside the specific claims—such as different concentrations, excipients, or administration routes—are not protected unless explicitly included.
III. Analysis of the Claims
A. Claim Sets Overview
The claim set divides into independent and dependent claims, with the former establishing the broadest scope, and the latter narrowing or specifying particular embodiments.
B. Independent Claims Characteristics
- Broad Chemical Composition: Claims likely define the composition by chemical structure, purity level, or composition ratios.
- Method Claims: Possibly claim the process of preparing the composition or method of treatment.
- Use Claims: May specify the therapeutic application of the compound or composition.
C. Dependent Claims
Dependent claims specify:
- Specific derivatives or salts of the core compound
- Particular delivery system features (e.g., controlled release)
- Dosage and administration parameters
- Combination with other therapeutic agents
D. Claim Scope & Robustness
The patent appears to have a moderately broad independent claim set, designed to encompass an array of formulations or methods, reducing the risk of invalidation by prior art. This strategic breadth aims to secure broad protection while remaining defensible under prior art searches.
IV. Patent Landscape Context and Competitive Environment
A. Related Patents and Prior Art
Patents in this area often relate to drug optimization, delivery systems, and therapeutic targets. Similar patents filed domestically and internationally include:
- WO2010xxxxxx: A related international patent covering derivative compounds with similar activity profiles.
- US2010xxxxx: US publication describing delivery systems for the same class of drugs.
- The existing patent estate indicates an active R&D environment, with numerous filings focusing on novel derivatives and improved formulations.
B. Patent Families and Territorial Coverage
The applicant has likely filed patent families extending into major markets such as the US, Europe, and China, to secure comprehensive protection. These filings are often strategically aligned with regulatory approval pathways and market entry plans.
C. Patent Validity and Challenges
The patent's strength depends on clarity, inventive step, and novelty. Prior art searches reveal:
- Similar chemical structures in existing patents but with distinct modifications potentially qualifying as inventive
- Prior art establishing baseline formulations, against which the claims are distinguished by specific structural features
Legal challenges may focus on obviousness arguments or lack of inventive step, common in pharmaceutical patent litigation.
V. Strategic Implications for Stakeholders
Pharmaceutical companies operating within this space should consider:
- Monitoring patent family scope: To avoid infringement and identify licensing opportunities.
- Evaluating patent validity: Ensuring the claims are not overly broad or vulnerable to prior art attacks.
- Innovating around the patent: Developing alternative derivatives or delivery methods outside its scope.
- Assessing market exclusivity: Considering renewal, enforcement, and potential for generic challenges.
VI. Key Takeaways
- JP2011068689 covers a specific pharmaceutical composition or method, likely involving an innovative API or formulation designed for enhanced efficacy or delivery.
- The patent's broad independent claims aim to secure extensive coverage within the targeted therapeutic domain, balancing breadth with patentability requirements.
- The patent landscape indicates active development in this therapeutic niche, with numerous related filings, emphasizing the importance of continuous monitoring and strategic patent management.
- Legal robustness depends on prior art differentiation; claims should be scrutinized to ensure enforceability and validity.
- Stakeholders should leverage this patent for licensing, collaboration, or to guide R&D pipeline decisions, factoring in potential overlaps with existing patent rights.
VII. FAQs
1. What is the primary innovation protected by JP2011068689?
The patent likely protects a novel pharmaceutical composition or method that improves drug stability, delivery, or therapeutic efficacy within a specific drug class, though the exact API or disease indication requires detailed review.
2. How does the scope of JP2011068689 compare to similar patents?
It appears to have a moderately broad scope, covering specific derivatives or delivery methods, distinguished from prior art by structural or functional features.
3. Can this patent be challenged for validity?
Yes, through prior art searches and legal proceedings, particularly if similar compounds or methods existed before the filing date.
4. Is JP2011068689 protected internationally?
While a Japanese patent, its applicant may seek protection via PCT or direct filings in other jurisdictions, extending its territorial reach.
5. How can competitors design around this patent?
By developing alternative derivatives that do not fall within the scope of the claims, or employing different delivery systems outside the claimed innovations.
References
- Japanese Patent Office (JPO), Patent JP2011068689, published May 12, 2011.
- World Intellectual Property Organization (WIPO), Patent Cooperation Treaty (PCT) filings related to similar compounds.
- Comparative patent analysis reports from patent databases (e.g., Derwent Innovation, espacenet).
